Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

Anna Borodovsky, PhD, Kristina Yucius, Andrew Sprague, Nirmal K Banda, PhD, V. Michael Holers, MD, Akshay Vaishnaw, MD PhD, Martin Maier, PhD, Rajeev Kallanthottathil, PhD, Klaus Charisse, PhD, Satya Kuchimanchi, PhD, Muthiah Manoharan, PhD, David J Salant, MD, Kevin Fitzgerald, PhD, Rachel Meyers, PhD, Benny Sorensen, MD PhD

Blood (2014) 124 (21): 1606.

https://doi.org/10.1182/blood.V124.21.1606.1606

Published: 2014

Journal Articles

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Benny Sorensen, MD PhD, Tim Mant, MD, Akin Akinc, PhD, Amy Simon, MD, Lauren Melton, Christian Lynam, Andrew Strahs, PhD, Alfica Sehgal, PhD, Renta Hutabarat, PhD, Prasoon Chaturvedi, PhD, Scott Barros, PhD, Akshay Vaishnaw, MD PhD, Aln-AT Investigators

Blood (2014) 124 (21): 693.

https://doi.org/10.1182/blood.V124.21.693.693

Published: 2014

Journal Articles

Thrombelastographic Whole Blood Coagulation Parameters Demonstrate Improved Clot Strength Induced by Tranexamic Acid during Cardiopulmonary Bypass.

Benny Sørensen, MD, PhD, Thomas D. Christensen, MD, PhD, Mogens Harrits Jepsen, MD, Lars Folkersen, MD, Inge Severinsen, MD, Vibeke E. Hjortdal, MD, PhD, DMSc, Jørgen Ingerslev, MD, DMSc

Blood (2007) 110 (11): 3195.

https://doi.org/10.1182/blood.V110.11.3195.3195

Published: 2007

Journal Articles

Citrate Anticoagulant Artificially Masks the Hemostatic Effect of Recombinant Factor VIIA in Dilutional Coagulopathy.

Christian Fenger-Eriksen, MD, Jørgen Ingerslev, MD, DMSc, Else Tønnesen, MD, DMSc, Benny Sørensen, MD, PhD

Blood (2007) 110 (11): 3160.

https://doi.org/10.1182/blood.V110.11.3160.3160

Published: 2007

Journal Articles

Tranexamic Acid Increases Clot Stability in Patients with Severe Hemophilia A.

Anne-Mette Hvas, MD, PhD, Hanne Thykjaer Sorensen, Lisbeth Norengaard Sorensen, Kirsten Christiansen, Jorgen Ingerslev, MD, DMSc, Benny Sorensen, MD, PhD

Blood (2006) 108 (11): 1023.

https://doi.org/10.1182/blood.V108.11.1023.1023

Published: 2006

Journal Articles

Recombinant Factor VIIa Combined with Plasma Factor XIII Stabilize Clot Formation and Increase Clot Stability in Whole Blood from Patients with Severe Hemophilia A.

Benny Sorensen, MD, PhD, Rasmus Rojkjaer, Ph.D., Jorgen Ingerslev, MD, DMSC

Blood (2006) 108 (11): 1039.

https://doi.org/10.1182/blood.V108.11.1039.1039

Published: 2006

Journal Articles

Inhibitor Haemophilia A - Cases with Reduced Haemostatic Response to Wildtype rFVIIa Who Achieved a Normal Clotting Profile with a Novel Potent Analogue of rFVIIa.

Benny Sørensen, MD, PhD, Egon Persson, PhD, Jørgen Ingerslev, MD DMSc.

Blood (2005) 106 (11): 3215.

https://doi.org/10.1182/blood.V106.11.3215.3215

Published: 2005

NARROW

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Thrombelastographic Whole Blood Coagulation Parameters Demonstrate Improved Clot Strength Induced by Tranexamic Acid during Cardiopulmonary Bypass.

Citrate Anticoagulant Artificially Masks the Hemostatic Effect of Recombinant Factor VIIA in Dilutional Coagulopathy.

Tranexamic Acid Increases Clot Stability in Patients with Severe Hemophilia A.

Recombinant Factor VIIa Combined with Plasma Factor XIII Stabilize Clot Formation and Increase Clot Stability in Whole Blood from Patients with Severe Hemophilia A.

Inhibitor Haemophilia A - Cases with Reduced Haemostatic Response to Wildtype rFVIIa Who Achieved a Normal Clotting Profile with a Novel Potent Analogue of rFVIIa.

Email alerts

ASH Publications

American Society of Hematology

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Thrombelastographic Whole Blood Coagulation Parameters Demonstrate Improved Clot Strength Induced by Tranexamic Acid during Cardiopulmonary Bypass.

Citrate Anticoagulant Artificially Masks the Hemostatic Effect of Recombinant Factor VIIA in Dilutional Coagulopathy.

Tranexamic Acid Increases Clot Stability in Patients with Severe Hemophilia A.

Recombinant Factor VIIa Combined with Plasma Factor XIII Stabilize Clot Formation and Increase Clot Stability in Whole Blood from Patients with Severe Hemophilia A.

Inhibitor Haemophilia A - Cases with Reduced Haemostatic Response to Wildtype rFVIIa Who Achieved a Normal Clotting Profile with a Novel Potent Analogue of rFVIIa.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only